Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 6/20 | 0.68 |
| ▸ | REN | P00797 | 4/20 | 0.68 |
| ▸ | DPP4 | P27487 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | LTA4H | P09960 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | PEPD | P12955 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
| ▸ | THPO | P40225 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.55 |
| ▸ | FAP | Q12884 | 1/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL757253 | 1.00 | ACE (0.68) | ACERENDPP4KDM4EF2 | |
| SCHEMBL28776343 | 1.00 | ACE (0.68) | ACERENDPP4KDM4EF2 | |
| SCHEMBL7293351 | 0.89 | ACE (0.57) | ACERENDPP4KDM4EF2 | |
| SCHEMBL26429410 | 0.89 | DPP4 (0.62) | ACERENDPP4KDM4EF2 | |
| SCHEMBL7293358 | 0.89 | ACE (0.57) | ACERENDPP4KDM4EF2 | |
| SCHEMBL12343758 | 0.88 | DPP4 (0.61) | ACERENDPP4KDM4EF2 | |
| SCHEMBL30356637 | 0.86 | ACE (0.59) | ACERENDPP4KDM4EF2 | |
| SCHEMBL30938247 | 0.86 | ACE (0.54) | ACERENDPP4KDM4EF2 | |
| SCHEMBL2739551 | 0.85 | ACE (0.56) | ACERENDPP4KDM4EF2 | |
| SCHEMBL29405754 | 0.85 | ACE (0.56) | ACERENDPP4KDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032595-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | Obschestvo S Ogranichennoi Otvetstvennostyu "sia Peptides" (RU) | 2009-03-11 | — | — | EP | claimed |
| WO-2007139435-A1 | PEPTIDE SUBSTANCE REVEALING AN IMMUNOGEROPROTECTIVE EFFECT, PHARMACEUTICAL COMPOSITION ON ITS BASE AND THE METHOD OF ITS APPLICATION | OBSCHESTVO S OGRANICHENNOI OTVETSVENNOSTYU 'SIA PEPTIDES' (RU) | 2007-12-06 | — | — | WO | claimed |
| US-12612637-B2 | Compositions and methods for DHFR tunable protein regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-3894011-B1 | MEMBRANE BOUND IL12 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | OBSIDIAN THERAPEUTICS INC (US) | 2025-09-17 | — | — | EP | disclosed |
| EP-3443001-B1 | REGULATED BIOCIRCUIT SYSTEMS | OBSIDIAN THERAPEUTICS INC (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12227551-B2 | Membrane bound IL12 compositions and methods for tunable regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2025-02-18 | — | — | US | disclosed |
| US-20240401004-A1 | DHFR TUNABLE PROTEIN REGULATION | OBSIDIAN THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-12104178-B2 | DHFR tunable protein regulation | OBSIDIAN THERAPEUTICS, INC. (US) | 2024-10-01 | — | — | US | disclosed |
| EP-3806888-B1 | PDE5 DERIVED REGULATORY CONSTRUCTS AND METHODS OF USE IN IMMUNOTHERAPY | OBSIDIAN THERAPEUTICS INC (US) | 2024-01-31 | — | — | EP | disclosed |
| CN-110831961-B | CD19 compositions and methods for immunotherapy | 黑曜石疗法公司 | 2024-01-02 | — | — | CN | disclosed |
| US-11666642-B2 | PDE5 compositions and methods for immunotherapy | OBSIDIAN THERAPEUTICS, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-5340731-A | Genetaic engineering | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1994-08-23 | — | — | US | disclosed |
| WO-1993021331-A2 | POLYSACCHARIDE BINDING FUSION PROTEINS AND CONJUGATES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-10-28 | — | — | WO | disclosed |
| US-5202247-A | Hybrid protein containing polypeptide fused to substrate binding region of amino acid sequence | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1993-04-13 | — | — | US | disclosed |
| US-5137819-A | CELLULOSE BINDING FUSION PROTEINS FOR IMMOBILIZATION AND PURIFICATION OF POLYPEPTIDES | UNIVERSITY OF BRITISH COLUMBIA (CA) | 1992-08-11 | — | — | US | disclosed |
| EP-0372005-A4 | EXPRESSION SYSTEMS FOR PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS. | ONCOGEN (US) | 1990-06-26 | — | — | EP | disclosed |
| EP-0372005-A1 | EXPRESSION SYSTEMS FOR PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS | ONCOGEN (a Limited Partnership) (US) | 1990-06-13 | — | — | EP | disclosed |
| WO-1990000609-A1 | CELLULOSE BINDING FUSION PROTEINS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 1990-01-25 | — | — | WO | disclosed |
| WO-1989003886-A1 | EXPRESSION SYSTEMS FOR PREPARATION OF POLYPEPTIDES IN PROKARYOTIC CELLS | ONCOGEN, A LIMITED PARTNERSHIP (US) | 1989-05-05 | — | — | WO | disclosed |
| EP-0163406-A1 | Novel polypeptide expression method | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 1985-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612637-B2 | Compositions and methods for DHFR tunable protein regulation | DHFR, SHMT1, MTHFD1 | ACE 4301/4885REN 3979/4885DPP4 4590/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.